- Home
- SPRU vs OTLK Comparison
SPRU vs OTLK Comparison
Compare SPRU & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRU
- OTLK
- Stock Information
- Founded
- SPRU 2008
- OTLK 2010
- Country
- SPRU United States
- OTLK United States
- Employees
- SPRU N/A
- OTLK N/A
- Industry
- SPRU Auto Parts:O.E.M.
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPRU Consumer Discretionary
- OTLK Health Care
- Exchange
- SPRU Nasdaq
- OTLK Nasdaq
- Market Cap
- SPRU 48.7M
- OTLK 42.8M
- IPO Year
- SPRU N/A
- OTLK 2016
- Fundamental
- Price
- SPRU $5.02
- OTLK $1.84
- Analyst Decision
- SPRU
- OTLK Buy
- Analyst Count
- SPRU 0
- OTLK 5
- Target Price
- SPRU N/A
- OTLK $5.25
- AVG Volume (30 Days)
- SPRU 886.1K
- OTLK 4.5M
- Earning Date
- SPRU 11-11-2025
- OTLK 12-26-2025
- Dividend Yield
- SPRU N/A
- OTLK N/A
- EPS Growth
- SPRU N/A
- OTLK N/A
- EPS
- SPRU N/A
- OTLK N/A
- Revenue
- SPRU $108,010,000.00
- OTLK $1,505,322.00
- Revenue This Year
- SPRU $2.12
- OTLK N/A
- Revenue Next Year
- SPRU N/A
- OTLK $342.80
- P/E Ratio
- SPRU N/A
- OTLK N/A
- Revenue Growth
- SPRU 39.22
- OTLK N/A
- 52 Week Low
- SPRU $1.13
- OTLK $0.79
- 52 Week High
- SPRU $6.11
- OTLK $5.18
- Technical
- Relative Strength Index (RSI)
- SPRU 55.25
- OTLK 65.52
- Support Level
- SPRU $4.21
- OTLK $1.76
- Resistance Level
- SPRU $6.11
- OTLK $2.09
- Average True Range (ATR)
- SPRU 0.77
- OTLK 0.19
- MACD
- SPRU 0.07
- OTLK 0.06
- Stochastic Oscillator
- SPRU 51.78
- OTLK 70.31
About SPRU Spruce Power Holding Corporation
Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.